Skip to main content

Vera Therapeutics, Inc. (VERA)

NASDAQ: VERA · IEX Real-Time Price · USD
17.09 0.54 (3.26%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap352.14M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out10.50M
EPS (ttm)-19.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume16,035
Open16.43
Previous Close16.55
Day's Range16.22 - 17.44
52-Week Range11.30 - 33.45
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About VERA

Vera Therapeutics is a clinical stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. We are conducting a Phase 2b clinical trial of atac...

IndustryBiotechnology
IPO DateMay 14, 2021
CEOMarshall Fordyce, M.D.
Employees13
Stock ExchangeNASDAQ
Ticker SymbolVERA
Full Company Profile

Financial Performance

Financial Statements

News

Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidn...

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases ...

1 week ago - GlobeNewsWire

Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases...

1 month ago - GlobeNewsWire

Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases ...

2 months ago - GlobeNewsWire

Vera Therapeutics Appoints Sean Grant as Chief Financial Officer

Healthcare and financial services industry veteran brings nearly 15 years of multi-disciplinary financial experience and proven track record in strategic investments, equity capital markets, and partner...

3 months ago - GlobeNewsWire

Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Completed an initial public offering with net proceeds, including the exercise of the underwriters' option in full, of approximately $48.4 million in May 2021 - - - Expanded the management team to suppo...

3 months ago - GlobeNewsWire

Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative trea...

4 months ago - GlobeNewsWire

Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share

Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The biotech will start trading on NAS...

5 months ago - Benzinga

Vera Therapeutics Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments...

5 months ago - GlobeNewsWire

Vera Therapeutics IPO Registration Document (S-1)

Vera Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC